RDPAC药品推广行为准则 - IFPMA

断药品等。
• “推广”指由某会员公司
通过各种方式——包括互
联网,以促进其药品的处
方、推荐、供应、用于病
人或为病人自用等为目的
的,针对医疗卫生专业人
士所进行的或组织、赞助
的任何行为或活动。
• “医疗卫生专业人士”
指医疗、牙科、药剂或护
理领域中的专业人员,或
其他任何在其专业活动中
可能开具药品处方或推
荐、采购、供应药品或将
药品用于病人的人员。
• “医疗机构”一般指由医
疗专业人士组成的机构,
或提供医疗服务、和/或
进行医疗研究的机构。
• “会员公司”指依法在中
国境外成立或组建、在中
国境内有实质性投资或经
营性投资并成为RDPAC
会员公司的研发类制药企
业,包括外商投资企业或
blood products, diagnostic aids,
etc.
• “promotion” means any activity
undertaken, organized or sponsored
by a member company
which is directed at healthcare
professionals to promote the
prescription, recommendation,
supply, administration or consumption
of its pharmaceutical
product(s) through all methods
of communications, including the
internet.
• “healthcare professional” means
any member of the medical, dental,
pharmacy or nursing professions
or any other person who in
the course of his or her professional
activities may prescribe,
recommend, purchase, supply,
or administer a pharmaceutical
product.
• “medical institution” means
typically an organization that is
comprised of healthcare professionals
and/or that provides
healthcare or conducts healthcare
research.
• “member company” means any
R&D-based phar maceutical
company lawfully established or
incorporated outside of China
with substantial investment or
operational interests in China that
became a member of RDPAC,
including a foreign-invested enterprise
or other legal entity reg-
17
研
制
开
发
制
药
企
业
协
会